Institutional money is constantly shifting, but the most aggressive alpha is often found before the broader market catches on. We have scanned the data for high-growth, undervalued assets showing heavy momentum and technical accumulation. These three under-the-radar equities—spanning critical metals, deep biotech, and tech infrastructure—present compelling risk-reward setups for the coming quarters.
1. Selkirk Copper Mines Inc. (TSXV: SCMI)
- Sector: Materials / Junior Mining
- Market Cap: ~$254M CAD
- The Catalyst: Copper supply constraints are a dominant global macroeconomic theme. Selkirk is currently advancing the Minto Copper-Gold-Silver mine in the Yukon. Demonstrating significant financial backing, they recently closed a heavily oversubscribed and upsized $35 million bought-deal financing to accelerate site operations and launch a massive 50,000-metre Phase 2 drill program.
- Technical Setup: Exceptional momentum. The chart shows a multi-bagger run from its 52-week lows (~$0.42) to the current $1.95 CAD range. Volume profiles indicate sustained institutional accumulation, and strong participation in recent financings confirms high conviction. This is a premier copper restart play with serious upside before retail volume fully arrives.
2. Lineage Cell Therapeutics, Inc. (NYSE: LCTX)
- Sector: Biotechnology
- Market Cap: ~$320M USD
- The Catalyst: Operating in the clinical-stage space, Lineage focuses on innovative cell replacement therapies for serious medical conditions. What separates LCTX from typical cash-burning small-cap biotech is a pristine balance sheet. They operate completely debt-free with a strong cash position—funding operations into Q2 2028—allowing them to advance their clinical pipeline and proprietary platforms (like AlloSCOPE) without the immediate threat of shareholder dilution.
- Technical Setup: Finding strong fundamental support levels. Biotech requires patience, but LCTX is positioned as a highly undervalued asset given its intellectual property and cash runway. Chart momentum is establishing a firm base, making it an attractive entry point for growth seekers wanting exposure to next-generation therapeutics before major clinical readouts.
3. TSS, Inc. (NASDAQ: TSSI)
- Sector: Information Technology / Data Infrastructure
- Market Cap: ~$365M USD
- The Catalyst: As the AI workforce and data center boom continues, the infrastructure required to physically house and maintain these systems is highly lucrative. TSS specializes in enterprise system integration, rack assembly, and data center facilities management. Riding the AI wave, they recently reported a massive 88% year-over-year surge in systems integration revenue for Q1 2026, drastically outpacing the broader IT sector average.
- Technical Setup: This is a pure revenue-growth play. With the demand side of AI infrastructure scaling globally, TSSI operates in a highly defensive yet high-growth niche. Despite the massive earnings beat, the stock remains largely underappreciated by major funds. The current accumulation phase offers a window before volume-weighted average prices start climbing into higher resistance bands.
